Russell Alan J 4
4 · Edgewise Therapeutics, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Russell Alan J
DirectorChief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-03-07−200→ 1,456,580 totalExercise: $0.18Exp: 2032-06-27→ Common Stock (200 underlying) - Exercise/Conversion
Common Stock
2025-03-07$0.18/sh+200$36→ 15,063 total - Sale
Common Stock
2025-03-07$30.02/sh−200$6,004→ 14,863 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This Option was fully vested on June 27, 2021.